PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …

Cutaneous melanoma is the deadliest and most aggressive form of skin cancer owing to its
high capacity for metastasis. Over the past few decades, the management of this type of …

Abstract Background Immune checkpoint inhibitors (ICIs) have become a central part of
cancer care. However, the survivorship outcomes in patients treated with ICIs are …

Abstract Background Immune checkpoint inhibitors (ICIs) may induce persistent immune-
related adverse events (irAEs). We investigated persistent irAEs and implications on …

Background: Immunotherapy has drastically changed the outlook for melanoma patients
over the past decade. Specifically, the dual blockade of immune checkpoints using …

An individual may be considered a cancer survivor from diagnosis through the balance of
their life. 1 In contrast to those with early-stage cancer, survivorship care for people with …

Abstract Background Immune checkpoint inhibitors (ICIs) have significantly improved the
overall survival of patients with metastatic melanoma. It is unclear how the growing group of …

Simple Summary In the era of immunotherapy, advanced melanoma patients have
unprecedentedly higher survival rates. However, the application of immunotherapy may lead …

Background Immune checkpoint inhibitors (ICI) and targeted therapies (TT) have
significantly improved disease control and survival in people with stage III and IV cutaneous …

Purpose Immunotherapy (IT) and targeted therapy (TT) have improved survival for some
patients with metastatic non-small cell lung cancer (NSCLC). Their lived experience is under …